Dla Emergent Iv Research And Development Program

Deadline: 12 Jun 2027

United States

Ref. No.: 6345486

EMD:Ref Document

Bid Value: Ref Document

571 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6344888

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Colistin Atc J01Xb01 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6340118

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Albendazole Atc P02Ca03 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6337365

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Pomalidomide Atc L04Ax06 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6335525

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6322269

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

The Provision Of Specialist Substance Use Detoxification And Rehabilitation Services Lcc37252

Deadline: 31 Jul 2034

Great Britain

Ref. No.: 6321422

EMD:Ref Document

Bid Value: Ref Document

3177 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 6321334

EMD:Ref Document

Bid Value: Ref Document

408 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6320404

EMD:Ref Document

Bid Value: Ref Document

199 Days Left

Genomedia A Personalized Medicine Tool For Diabetes

Deadline: 31 Jan 2026

Spain

Ref. No.: 6318707

EMD:Ref Document

Bid Value: Ref Document

74 Days Left

Demonstrating Innovative Pathways Addressing Water And Soil Pollution In The Mediterranean Agro Hydro System

Deadline: 30 Jun 2028

Greece

Ref. No.: 6318627

EMD:Ref Document

Bid Value: Ref Document

955 Days Left

Open House Biologics Discount Agreements 2024 05 Ustekinumab

Deadline: 31 Jul 2026

Germany

Ref. No.: 6313745

EMD:Ref Document

Bid Value: Ref Document

255 Days Left

Open House Biologics Discount Agreements 2024 07 Epoetin Zeta

Deadline: 31 Jul 2026

Germany

Ref. No.: 6311643

EMD:Ref Document

Bid Value: Ref Document

255 Days Left

Applicant Tracking System

Deadline: 16 Jul 2026

United States

Ref. No.: 6310887

EMD:Ref Document

Bid Value: Ref Document

240 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 6261602

EMD:Ref Document

Bid Value: Ref Document

408 Days Left

Discover Tenders by Parts Hand Tools Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Parts Hand Tools Sector

Filter Your Search

FREE Trial plan for all new users!